New Japanese Data Bode Well For Shionogi’s OIC Drug
This article was originally published in PharmAsia News
Shionogi has released the first late-stage clinical results from patients in Japan for its novel opioid-induced constipation drug, the positive data setting the stage for a planned approval filing in this market before the end of the fiscal year.
You may also be interested in...
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.